Back to today’s briefing

Story perspectives

Verve's Gene Therapy Cuts LDL Cholesterol by 69%

4/17/2025

27 2

Summary

Story summary

Verve Therapeutics is making waves in heart disease treatment with its groundbreaking VERVE-102 gene editing therapy, which slashed LDL cholesterol levels by an impressive 69% in a Phase 1b trial of 14 high-risk patients. This innovative one-time infusion targets the PCSK9 gene, offering hope for a healthier future without serious side effects. A Phase 2 trial is on the horizon for late 2025.

1 of 1

Story summary

Verve Therapeutics is making waves in heart disease treatment with its groundbreaking VERVE-102 gene editing therapy, which slashed LDL cholesterol levels by an impressive 69% in a Phase 1b trial of 14 high-risk patients. This innovative one-time infusion targets the PCSK9 gene, offering hope for a healthier future without serious side effects. A Phase 2 trial is on the horizon for late 2025.